Shepherin II Gene Synthesis and Peptide Characterization: E. coli Expression, Purification, and Antiviral Activity

Bibliographic Information
Authors: Elfattah A.A.; Samir S.; Okasha H.; Atef A.A.; Taha A.
Journal: Protein and Peptide Letters
Publisher: Bentham Science Publishers
Publication Date: October 2026
Volume / Issue: Volume 32 / Issue 10
Pages: 756–768
ISSN: 9298665
DOI: 10.2174/0109298665413796251002111415
Scopus: View on Scopus
PubMed: 41140082
Document Type: Article
Authors and Affiliations
Elfattah A.A., Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo, 11566, Egypt; Samir S., Department of Biochemistry and Molecular Biology, Theodor Bilharz Research Institute, Giza, 12411, Egypt; Okasha H., Department of Biochemistry and Molecular Biology, Theodor Bilharz Research Institute, Giza, 12411, Egypt; Atef A.A., Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo, 11566, Egypt; Taha A., Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo, 11566, Egypt
Abstract
Introduction: The shepherin II peptide is characterized by a histidine/glycine-rich sequence. This study aimed to design, express recombinantly, and evaluate the antiviral activity of shepherin II against hepatitis A virus (HAV). Methods: The shepherin II gene was reverse-translated, cloned into the pET-3a vector, and expressed in E. coli BL21 (DE3) pLysS cells induced with 2 mM IPTG. Purification was achieved via cation exchange chromatography, and intact mass analysis using mass spectrometry was carried out. Cytotoxicity on normal Vero cells and antiviral activity on HAV were evaluated. Results: The mass spectrometry confirmed a primary peptide fragment with a molecular weight of 3,421.30 Da (100% relative abundance). SDS-PAGE verified peptide expression. Cytotoxicity tests on Vero cells showed a CC50 of 219.26 ± 7.91 µg/ml. Antiviral assay revealed an EC50 of 113.92 ± 4.58 µg/ml against HAV, resulting in a selectivity index (SI) of 1.92. This SI indicates limited selectivity compared to the reference drug amantadine, which exhibited an EC50 of 5.67 ± 0.71 µg/ml and an SI of 53.41. Discussion: The recombinant expression of shepherin II was successfully achieved and confirmed by mass spectrometry and SDS-PAGE. The peptide showed measurable antiviral activity against HAV. Conclusion: This study demonstrated the feasibility of recombinant shepherin II production and assessed its antiviral activity. However, the limited selectivity index of shepherin II remains a challenge that needs to be addressed through molecular modification or alternative delivery strategies to improve its clinical potential. 2025, Bentham Science Publishers
Keywords
antimicrobial peptide; antiviral activity; HAV; Histidine-glycine rich peptide; recombinant DNA technology; shepherin peptides; Animals; Antiviral Agents; Chlorocebus aethiops; Escherichia coli; Gene Expression; Hepatitis A virus; Peptides; Recombinant Proteins; Vero Cells; amantadine; antivirus agent; isopropyl thiogalactoside; shepherin II peptide; unclassified drug; peptide; recombinant protein; Article; bacterial gene; BL21 gene; CC50 (cytotoxic concentration); controlled study; cytotoxicity; cytotoxicity test; drug design; drug purification; drug synthesis; EC50; gene synthesis; ion exchange chromatography; mass spectrometry; molecular weight; nonhuman; peptide analysis; polyacrylamide gel electrophoresis; selectivity index; Vero cell line; animal; biosynthesis; chemistry; drug effect; genetics; isolation and purification; metabolism
Citation Information
Scopus Citations: 1
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
